Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
6(60%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_2
8
80%
Ph phase_1
1
10%
Ph phase_4
1
10%

Phase Distribution

1

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
8(80.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

10

all time

Status Distribution
Active(6)
Completed(3)
Other(1)

Detailed Status

Recruiting3
Completed3
Active, not recruiting3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
6
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 28 (80.0%)
Phase 41 (10.0%)

Trials by Status

unknown110%
recruiting330%
completed330%
active_not_recruiting330%

Recent Activity

6 active trials
Showing 5 of 10
active_not_recruitingphase_2

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

NCT04653246
active_not_recruitingphase_2

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

NCT04151667
recruitingphase_2

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

NCT04268199
completedphase_2

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

NCT04131309
active_not_recruitingphase_2

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

NCT04717700
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04653246Phase 2

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Active Not Recruiting
NCT04151667Phase 2

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Active Not Recruiting
NCT04268199Phase 2

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Recruiting
NCT04131309Phase 2

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Completed
NCT04717700Phase 2

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active Not Recruiting
NCT06572813Phase 1

Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

Recruiting
NCT02654990Phase 2

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Completed
NCT05248633Phase 2

Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

Recruiting
NCT04224571Phase 2

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Completed
NCT05135442Phase 4

Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

Unknown

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10